Mictonorm

Propiverine Hydrochloride, the active ingredient in Mictonorm, is an antimuscarinic presented as an oral formulation for systemic use. It reduces involuntary bladder contractions and is indicated for the treatment of overactive bladder symptoms, including urgency, frequency and urge incontinence, in adult patients. The product complies with European Union marketing‑authorisation requirements and is manufactured under GMP conditions. It is widely used in clinical practice for managing bladder overactivity.

GNH USA supplies Mictonorm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide across multiple continents.

Mictonorm, an antimuscarinic agent, acts on the detrusor muscle pathway to control overactive bladder symptoms. - Overactive bladder: reduces urgency and frequency by decreasing involuntary detrusor contractions. - Urinary frequency: lowers the number of daily voids through bladder muscle relaxation. - Urinary urgency: diminishes sudden strong urges to void. - Urge urinary incontinence: helps prevent involuntary leakage associated with urgency.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Constipation: slowed gastrointestinal motility. - Blurred vision: transient ocular accommodation changes. - Headache: mild to moderate intensity. - Dizziness: occasional light‑headedness. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Acute urinary retention: inability to void requiring medical intervention. - Severe constipation: risk of bowel obstruction. - Allergic reactions: rash, pruritus, or angioedema. - Tachycardia: elevated heart rate. - Hepatic enzyme elevation: abnormal liver function tests. - QT interval prolongation: potential cardiac arrhythmia.

Precautions should be observed when prescribing Mictonorm. - Renal impairment: assess renal function and adjust therapy as needed. - Hepatic impairment: monitor liver enzymes regularly. - Elderly patients: increased susceptibility to anticholinergic effects. - History of urinary retention: use with caution or avoid. - Concomitant anticholinergics: avoid additive anticholinergic burden. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Mictonorm may interact with several medications. Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase propiverine plasma concentrations. - Potent anticholinergic agents: additive anticholinergic effects can be hazardous. - QT‑prolonging drugs: combined use may raise the risk of cardiac arrhythmias. Moderate Interactions (Monitor Closely): - Diuretics: may alter bladder volume and affect efficacy. - Beta‑agonists: potential reduction in therapeutic benefit. - Antihistamines: may increase anticholinergic side‑effects.